Procrit Sales Data

Rank 63 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Procrit U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 63 (12) -10.09% -10.00%
Q3 2013 51 (4) 5.08% 2.47%
Q2 2013 55 (6) 6.00% 4.81%
Q1 2013 61 (3) -2.24% -3.23%
Q4 2012 58 (1) -6.07% -4.45%
Q3 2012 57 (10) -10.20% -7.59%
Q2 2012 47 (11) 10.72% 7.12%
Q1 2012 58 (3) -2.13% -4.22%
Q4 2011 55 (2) 3.58% 3.01%
Q3 2011 53 (12) -21.61% -21.32%
Q2 2011 41 (7) 7.04% 5.56%
Q1 2011 48

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
June 24, 2011Janssen Products, LP Modifies Prescribing Information for PROCRIT (Epoetin alfa) in Chronic Kidney Disease
June 24, 2011FDA Modifies Dosing Recommendations for Erythropoiesis-Stimulating Agents
October 19, 2010FDA Advisers Back Anemia Drugs for Kidney Patients
October 19, 2010FDA Panel Backs Anemia Drugs For Kidney Disease
February 16, 2010FDA Tightens Controls on Anemia Drugs
December 3, 2008FDA Issues Questions and Answers on Medication Guides for Erythropoiesis-stimulating Agents (ESAs).
November 24, 2008Study Calls for Greater Scrutiny of 'Off-Label' Drug Use
September 26, 2008Anemia Drugs Linked to Stroke Study Deaths: FDA
Hide
(web5)